PMA device
SetPoint System
SetPoint Medical · Vagus Nerve Stimulator For Rheumatoid Arthritis (SFJ, Class III) · First FDA decision Jul 30, 2025, newest Jan 16, 2026
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
9
Naming "SetPoint"
MAUDE reports
2
Brand "SetPoint", since 2015
PubMed studies
2,523
Mentioning "SetPoint"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SetPoint System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- SetPoint SystemPMA supplement
P240039-S001 · Decided Jan 16, 2026 · 142 days after receipt · Normal 180 Day Track No User Fee
Device type: Vagus nerve stimulator for rheumatoid arthritis (SFJ) · Neurology & Neurosurgery
- SetPoint SystemBreakthroughPMA
P240039 · Decided Jul 30, 2025 · 268 days after receipt
Device type: Vagus nerve stimulator for rheumatoid arthritis (SFJ) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Vagus Nerve Stimulation (VNS)National determinationOn the books160.18Updated Nov 5, 2026
- Vagus Nerve Stimulation for Treatment of Resistant Depression (TRD)National analysisReview closedCAG-00313RUpdated Sep 24, 2026
- Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression (TRD)National analysisReview closedCAG-00313R2Updated Sep 24, 2026
- Extracorporeal Immunoadsorption Using Protein A Columns for Rheumatoid ArthritisNational analysisReview closedCAG-00057NUpdated Sep 14, 2026
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Phrenic Nerve StimulatorNational determinationOn the books160.19Updated Jun 12, 2020
- MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid ArthritisLocal determinationIn effectL39427CGS Administrators, LLCUpdated Jul 2, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "SetPoint", any status and sponsor, newest update first.
- Vagus Nerve Stimulation for Moderate to Severe Rheumatoid ArthritisPivotal-lookingActive, not recruiting
SetPoint Medical CorporationNot on our public-company list
NCT04539964 · 243 participants · Start Jan 11, 2021 · Primary completion May 16, 2024
Device: Active stimulation; Non-active stimulation · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 43 sites in all
- Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)Active, not recruiting
SetPoint Medical CorporationNot on our public-company list
NCT04862117 · 14 participants · Start Jul 28, 2018 · Primary completion Dec 8, 2026
Device: SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System · For: Rheumatoid Arthritis
Sites: Aventura, Florida; Zephyrhills, Florida; Great Neck, New York · 4 sites in all
SetPoint Medical CorporationNot on our public-company list
NCT06796504 · 60 participants (planned) · Start Apr 17, 2026 · Primary completion Dec 31, 2027
Device: Active stimulation; Non-active stimulation · For: Relapsing Remitting Multiple Sclerosis
Sites: Irvine, California; Atlanta, Georgia; Baltimore, Maryland · 9 sites in all
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SetPoint", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code SFJ
3 reports: 0 malfunction, 2 injury, 0 death
Newest reports for this brand
- SetPoint SystemInjury
3013688988-2026-00002 · Received Oct 2, 2026 · Event dated Sep 4, 2026
Device type: Vagus Nerve Stimulator For Rheumatoid Arthritis (SFJ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hypersensitivity/Allergic reaction
- SETPOINT SYSTEMInjury
3013688988-2026-00001 · Received Jun 26, 2026 · Event dated May 14, 2026
Device type: Vagus Nerve Stimulator For Rheumatoid Arthritis (SFJ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Low White Blood Cell Count
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SetPoint"[tiab]. The summary above synthesizes these.
- LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity.
Krishnamurty AT, Shyer JA, Thai M, et al. · Nature · 2022Research Support, Non-U.S. Gov't
- Neuromodulation and Individuality.
Maloney RT · Front Behav Neurosci · 2021Review
- Tumor cell-intrinsic epigenetic SETpoint of cancer-associated fibroblasts.
Chen X, Huang H · Cancer Cell · 2024Research Support, N.I.H., Extramural, Comment
- Mammalian hibernation.
Nedergaard J, Cannon B · Philos Trans R Soc Lond B Biol Sci · 1990Review
- Cytokines in Febrile Diseases.
Lai J, Wu H, Qin A · J Interferon Cytokine Res · 2021Research Support, Non-U.S. Gov't, Review
- Beyond the fixed setpoint of the hypothalamus-pituitary-thyroid axis.
Fliers E, Kalsbeek A, Boelen A · Eur J Endocrinol · 2014Review
- From appetite setpoint to appetition: 50years of ingestive behavior research.
Sclafani A · Physiol Behav · 2018Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Thermoregulation and hyperthermia.
Lenhardt R, Kurz A, Sessler DI · Acta Anaesthesiol Scand Suppl · 1996
- The Analysis of Gravitropic Setpoint Angle Control in Plants.
Roychoudhry S, Del Bianco M, Kepinski S · Methods Mol Biol · 2022
- Opposing GPCR signaling programs protein intake setpoint in Drosophila.
Wu G, Ma T, Hancock CE, et al. · Cell · 2024
- Individual differences in social homeostasis.
Bales KL, Hang S, Paulus JP, et al. · Front Behav Neurosci · 2023Review
- Explaining happiness.
Easterlin RA · Proc Natl Acad Sci U S A · 2003Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.